![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » BRISTOL-MYERS SQUIBB COMPANY AND MEDIVIR AB ANNOUNCE WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE MIV-170 FOR THE TREATMENT OF HIV-1 INFECTION IN ADULTS
BRISTOL-MYERS SQUIBB COMPANY AND MEDIVIR AB ANNOUNCE WORLDWIDE COLLABORATION TO DEVELOP AND COMMERCIALIZE MIV-170 FOR THE TREATMENT OF HIV-1 INFECTION IN ADULTS
September 13, 2006
Bristol-Myers Squibb Company and Medivir AB announced a worldwide collaboration to develop and commercialize MIV-170, a preclinical non-nucleoside reverse transcriptase inhibitor, or NNRTI, intended for the treatment of HIV-1 infection in adults as part of an antiretroviral drug regimen. BioSpace (http://www.biospace.com/news_story.aspx?StoryID=29794&full=1)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct